| Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. | |
| | |
MedLine Citation:
|
PMID: 19363847 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hypertension is a major co-morbidity for type 2 diabetes, and an important modifiable risk factor for vascular events. Therefore, treatment of diabetes and its risk factors is important to minimize complications, and much progress has been made over the past 30 years. The UKPDS trial showed that intensive glycaemic and blood pressure control reduced the risk of vascular events. In the HOT study, the addition of aspirin to patients with diabetes and controlled hypertension decreased the risk of myocardial infarction. Blood pressure control with angiotensin-converting enzyme inhibitors in MICRO-HOPE also showed significant reductions in the risk of vascular complications, and blockers of the renin-angiotensin system produced substantial renal protective effects in patients with hypertension and diabetes. Statin therapy in the HPS and CARDS studies was effective in the primary prevention of cardiovascular disorders. Finally, an intensive multifactorial intervention achieved sustained reduction in the risk of vascular complications and death in patients with type 2 diabetes in the Steno-2 study. Nevertheless, the major coronary event risk remains high in type 2 diabetes patients, and the results of the ADVANCE trial provided a step forward in treatment. |
| | |
Authors:
|
Jean-Jacques Mourad; Sylvain Le Jeune |
Related Documents
:
|
11467307 - Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes ... 19125897 - Inhibiting the renin-angiotensin system: why and in which patients. 17307057 - Global risk management in patients with type 2 diabetes mellitus. 20584997 - Health insurance status and control of diabetes and coronary artery disease risk factor... 8013757 - Reduced na(+)-k(+)-atpase activity and plasma lysophosphatidylcholine concentrations in... 9611157 - Extreme hyperinsulinemia unmasks insulin's effect to stimulate protein synthesis in the... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of hypertension. Supplement : official journal of the International Society of Hypertension Volume: 26 ISSN: 0952-1178 ISO Abbreviation: J Hypertens Suppl Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2009-04-14 Completed Date: 2009-05-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8501422 Medline TA: J Hypertens Suppl Country: England |
Other Details:
|
Languages: eng Pagination: S7-13 Citation Subset: IM |
Affiliation:
|
Hypertension Unit, Avicenne University Hospital (AP-HP) and Paris 13 University (EA 3412), 93000 Bobigny, France. jean-jacques.mourad@avc.aphp.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antihypertensive Agents
/
therapeutic use Blood Pressure* Diabetes Mellitus, Type 2 / drug therapy, mortality* Humans Hypertension / drug therapy, mortality* Hypoglycemic Agents / therapeutic use Prognosis Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Hypoglycemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Global nurse migration: its impact on developing countries and prospects for the future.
Next Document: From macro- to microcirculation: benefits in hypertension and diabetes.